Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 9/20 | 0.41 |
| ▸ | KRAS | P01116 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980006 | 0.89 | HDAC6 (0.45) | GSRHDAC6DRD2DRD4GRM2 | |
| SCHEMBL3977544 | 0.85 | HDAC6 (0.54) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3981485 | 0.85 | HDAC6 (0.54) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3977550 | 0.85 | HDAC6 (0.54) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3985128 | 0.73 | HDAC6 (0.54) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3985125 | 0.73 | HDAC6 (0.54) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3979742 | 0.71 | HDAC6 (0.52) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3979744 | 0.71 | HDAC6 (0.52) | HDAC6ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL3980138 | 0.71 | HDAC6 (0.52) | HDAC6ALDH1A1PHGDHKDM4ESMN1; SMN2 | |
| SCHEMBL3980135 | 0.71 | HDAC6 (0.52) | HDAC6ALDH1A1PHGDHKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| EP-1620409-A1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | GSR 838/4885HDAC6 1300/4885NTRK1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.